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More than 100 transthyretin (TTR) variants are associated with hereditary amyloidosis. Approaches
for TTR amyloidosis that interfere with any step of the cascade of events leading to ﬁbril formation
have therapeutic potential. In this study we tested ()-epigallocatechin-3-gallate (EGCG), the most
abundant catechin of green tea, as an inhibitor of TTR amyloid formation. We demonstrate that
EGCG binds to TTR ‘‘in vitro” and ‘‘ex vivo” and that EGCG inhibits TTR aggregation ‘‘in vitro” and
in a cell culture system. These ﬁndings together with the low toxicity of the compound raise the pos-
sibility of using EGCG in a therapeutic approach for familial amyloidotic polyneuropathy, the most
frequent form of hereditary TTR amyloidosis.
Structured summary:
MINT-7294529: TTR (uniprotkb:P02766) and TTR (uniprotkb:P02766) bind (MI:0407) by comigration in
non-denaturing gel electrophoresis (MI:0404)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Recent studies revealed that the polyphenol ()-epigallocate-
chin gallate (EGCG), the most abundant catechin in green tea,
may be used for the prevention and treatment of diseases involving
amyloid ﬁbril formation [1,2]. In the particular case of neurodegen-
erative diseases, it was shown that EGCG inhibits both a-synuclein
and amyloid-b ﬁbrillogenesis [1]. In both instances, protein aggre-
gation is a key factor for the development of the disease. That is
also the case of transthyretin (TTR) amyloidoses that are protein
aggregation diseases associated with peripheral neuropathy. More
than 100 TTR variants with a single amino acid substitution have
been related to hereditary amyloidosis [3]. The most frequent var-
iant is TTR V30M, in which a residue of valine (V) is substituted by
a methionine (M) originating a particular form of the disease des-
ignated familial amyloid polyneuropathy (FAP) [4]. Other TTR vari-chemical Societies. Published by E
GCG, ()-Epigallocatechin-3-
olecular, IBMC – Instituto de
85 Porto, Portugal. Fax: +351
a).ants are associated with more or less aggressive pathologies. For
instance, TTR L55P is associated with the most aggressive form of
the disease and is the most amyloidogenic TTR variant known. Iso-
lated TTR L55P easily forms ﬁbrils in physiological conditions (pH
7.4, 37 C) [5]. TTR Y78F is also a variant very prone to amyloid for-
mation. In the soluble form, this variant presents epitopes common
to TTR amyloid ﬁbrils thus resembling an early intermediate of TTR
ﬁbrillogenesis [6]. Therefore, this variant can be used to screen
inhibitors at very early stages of amyloid ﬁbril formation.
The amyloidogenic potential of TTR variants has been related to
the stability of the TTR tetramer [7]. The TTR molecule is a tetramer
of identical subunits of 127 amino acid residues each [8]. The occur-
rence of amino acid substitutions in the monomer induces subtle
structural alterations that decrease the stability of the tetramer that
dissociates into conformational alteredmonomers that aggregate to
formamyloidﬁbrils [9,10]. Several small compoundshave been sug-
gested for TTR amyloidosis therapy. Those compounds might act as
inhibitors of TTR tetramer dissociation impairing amyloid ﬁbril for-
mation or as disruptors of TTR ﬁbrils [11]. Among those, there are
non-steroidal anti-inﬂammatory drugs (NSAIDs) or derivatives
[12] and natural substances such as ﬂavonoids [13] and xanthones
of plant origin [14]. Most of the compounds previously testedlsevier B.V. All rights reserved.
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ing to TTR but present lowbinding afﬁnity or low selectivity of bind-
ing to TTR and in some cases, high toxicity. Therefore it is of most
interest toﬁndbetter compounds to inhibit amyloidﬁbril formation.
EGCG is a natural compound with very low toxicity that has been
tried in different amyloidoses [15]. In the present work we evaluate
the ability of EGCG to bind to TTR, its capacity to stabilize the mole-
cule and to inhibit amyloid ﬁbril formation.2. Materials and methods
2.1. Plasma samples
Whole blood from seven TTR V30M heterozygote carriers and
from seven control individuals was collected with EDTA and centri-
fuged. The plasma was separated and frozen at 20 C.
2.2. Recombinant proteins
Recombinant wild-type TTR (TTR WT), TTR V30M, TTR L55P and
TTR Y78F variants were produced in a bacterial expression system
and puriﬁed as previously described [16].
2.3. EGCG competition with T4 for the binding to TTR
Five microliters of plasma or 10 lg of the recombinant protein
were incubated with [125I]T4 (speciﬁc radioactivity 1250 lCi/lg;
Perkin–Elmer, MA, USA) in the presence or absence of EGCG
(20 molar excess). EGCG (Sigma–Aldrich, USA) was solubilised
in water or phosphate buffer saline (PBS). The plasma proteins
were then separated by native PAGE. The gel was dried, subjected
to phosphor imaging (Typhoon 8600; Molecular Diagnostics,
Amersham Biosciences), and analyzed using the ImageQuant pro-
gram version 5.1.
Competition of EGCG with T4 for the binding to TTR WT was
quantitatively assayed by incubating TTR (30 nM) with a trace
amount of [125I]T4 and with increasing concentrations (0–10 lM)
of competitor, either T4 or EGCG. Bound T4 was separated from free
T4 by gel ﬁltration [16].
2.4. Nitroblue tetrazolium (NBT) staining assay
EGCG binding to TTR was assayed by nitroblue tetrazolium
(NBT) staining [17]. Recombinant TTR WT and TTR V30M were
incubated in the presence of 10 molar excess of EGCG for 2 h at
37 C, or PBS (as control) and separated by SDS–PAGE (15% poly-
acrylamide). The gels were either silver stained or electroblotted
onto nitrocellulose membrane (GE Healthcare). The membranes
were washed with water and stained with glycinate/NBT solution
(0.24 mM NBT in 2 M potassium glycinate, pH 10) for 20 min.
The membranes were again washed and stained with Ponceau S
(0.1% in 5% acetic acid) resulting in red stained bands, while the
NBT stained bands remained purple.
2.5. Mass spectrometry analysis
Recombinant WT TTR (2 mg/mL in PBS) was incubated at
37 C for 1 h in the presence or absence (control) of EGCG at
0.36 mM (10 molar excess).
The samples were diluted to 0.1 lg/lL in water:methanol:for-
mic acid (50:50:1). Electrospray mass spectrometry (ESI-MS) was
performed on a Q-TOF2 mass spectrometer (Micromass, Man-
chester, UK). Samples were applied at 10 lL/min ﬂow rate. The
needle voltage was 3000 V, source block at 80 C and desolvationtemperature was 150 C. Data were acquired with a MassLynx 4
data system (Micromass, Manchester, UK). ESI-MS spectra were
deconvoluted using the MaxEnt 1 algorithm.
2.6. Study of EGCG–TTR interaction by Isothermal Titration
Calorimetry (ITC)
The details of the microcalorimeter unit (ThermoMetric AB, Jär-
falla, Sweden) used have been described previously [18,19]. The
calorimetric vessel was ﬁlled with 0.9 mL of a 120 lM TTR solution
in 20 mM sodium phosphate, pH 8.0, and the titration consisted of
serial additions of a 1500 lM EGCG solution in the same buffer.
The experiments were performed at 308.15 ± 0.01 K. The heat of
dilution to correct the binding curves was the constant heat per
injection in the last ﬁve injections. Experiments were performed
in ‘‘fast mode”, and the curves were dynamically corrected [19],
integrated using the Origin 7 software and the heat evolved per
injection calculated, using the previously determined calibration
constant.
2.7. Assessment of TTR tetrameric stability by Isoelectric Focusing (IEF)
Brieﬂy, 30 lL of human plasma were incubated with 5 ll of
10 mM EGCG solution for 1 h at 37 C and subjected to native
PAGE. The TTR gel band was excised and applied to a partial dena-
turing (4 M urea) IEF gel containing 5% (v/v) ampholytes pH 4–6.5
(GE Healthcare) run at 1200 V for 6 h [16,20]. Proteins were stained
with Coomassie Blue, the gels were scanned (HP Scanjet 4470c;
Hewlett–Packard) and subjected to densitometry using the Image-
Quant program.
2.8. Studies of TTR aggregation and ﬁbril formation by Transmission
Electron Microscopy (TEM)
To study the effect of EGCG on TTR aggregation, soluble TTR
Y78F (2 mg/mL) in PBS was incubated at 37 C for 0, 2, 4 and 6 days
alone or with EGCG 0.36 mM (10 molar excess) or 3.6 mM
(100). Ultrastructural analysis of the samples was performed by
TEM as detailed previously [21].
To study the effect of EGCG on TTR ﬁbril formation, we used
pre-formed aggregates. TTR Y78F aggregates were prepared by
incubation of the soluble protein (2 mg/mL) for 2 days at 37 C,
pH 7.4, while TTR WT and TTR V30M aggregates were prepared
by acidiﬁcation of the protein solutions (2 mg/ml) with 0.05 M so-
dium acetate (pH 3.6) and incubation for 72 h at room tempera-
ture. The samples were centrifuged at 15 000g, 4 C for 30 min.
The pellets were re-suspended in water and the aggregated TTRs
were incubated at 37 C for 0, 4 and 6 days alone or with EGCG
3.6 mM. Conditions for TEM analysis were as described previously
[21].
2.9. Cell culture and dot-blot ﬁlter assay for aggregate detection
To test EGCG as inhibitor of TTR aggregation we used a rat
Schwannoma (RN22) (American Type Cell Collection) cell line sta-
bly co-transfected with TTR L55P cDNA and grown in conditions
previously described [21]. The cells were incubated for 48 h with
1 lM EGCG in the medium and then for further 3 days (80% cell
conﬂuence) with EGCG simultaneously with 100 lM ZnSO4. The
cells were then incubated with serum-free medium with ZnSO4
and EGCG for additional 24 h. TTR in the medium was quantiﬁed
by ELISA, and the volume corresponding to 500 ng was applied
onto a 0.2 lm pore cellulose acetate membrane ﬁlter (Schleicher
and Schuell) under vacuum. TTR aggregates, retained in the mem-
brane, were immunodetected using rabbit anti-human TTR anti-
body (DAKO) (1:500 dilution) followed by a secondary antibody,
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Detection was performed with ECL (GE Healthcare). Dot blots
were quantiﬁed using the ImageQuant program. Experiments were
repeated at least three times in duplicate. All values are expressed
as means ± S.E.M. Comparison between groups was made using the
Student’s t-test. A P value of less than 0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1. EGCG binding to TTR
To determine if EGCG competed with T4 for the binding to TTR
in plasma from heterozygote TTR V30M carriers and from control
individuals (Fig. 1A) and to recombinant TTR WT and TTR V30M
(Fig. 1B) the samples were incubated with [125I]T4 in the presence
or absence of EGCG. Subsequently the proteins were separated by
native PAGE [16]. In whole plasma, three main proteins bind T4 as
indicated in Fig. 1A: thyroxine binding globulin (TBG), albumin and
TTR. As expected, TTR V30M presented signiﬁcant lower band
intensity than TTR WT, both in plasma and recombinant, due to
lower binding afﬁnity to [125I]T4. However no signiﬁcant alteration
of the TTR band intensity was found when comparing the same
sample in the presence and absence of EGCG. This indicates that
EGCG did not compete with T4 for the binding to plasma TTR, nei-
ther in TTR V30M heterozygote carriers nor in control individuals.
Noteworthy, when incubated with EGCG, TTR presented a different
electrophoretic mobility suggesting that the catechin alters TTR
migration through binding in a region of the molecule other than
the T4 binding site. The results obtained with isolated WT and
V30M TTR (Fig. 1B) were consistent with the plasma ex vivo data
(Fig. 1A).
We also tested EGCG competition with [125I]T4 for the binding
to recombinant TTR WT by a quantitative assay [16]. EGCG did
not displace [125I]T4 from TTR meaning that it does not compete
with T4 for the binding to TTR (data not shown), conﬁrming the
above described data.
3.2. Characterization of the EGCG–TTR interaction
It has been reported that EGCG reacts with proteins forming
complexes that are speciﬁcally stained with NBT [22]. To investi-
gate EGCG binding to WT and V30M TTR, each protein was incu-
bated in the presence or absence (control) of EGCG and subjected
to SDS–PAGE. We included a bovine serum albumin (BSA) sample
as positive control for EGCG binding. After electrophoresis, the pro-
teins in the gel were either silver stained (Fig. 2IA) or electroblot-
ted onto a nitrocellulose membrane. The membranes wereFig. 1. Competition of EGCG with T4 for the binding to TTR in human plasma (A) and reco
analyzed by PAGE. TTR migration is altered for the samples incubated with EGCG.subsequently stained with Ponceau S (Fig. 2IB), to conﬁrm blotting
efﬁciency, followed by NBT/glycinate staining (Fig. 2IC). Samples
incubated with EGCG (+), TTR WT and V30M, showed purple pro-
tein bands after NBT staining, while no colour reaction occurred
in the controls (). Thus, EGCG binds to TTR and the interaction
is stable under the denaturing conditions of SDS–PAGE.
The stability of the EGCG–TTR interaction suggested that the
complex could be detected by MS analysis. Therefore, TTR WT
was incubated with EGCG and the MS analysis (Fig. 2II) showed a
peak with a mass of 14 523 Da while the TTR alone presented a
peak of 14 065 Da. The mass difference between these two peaks
is 458 Da, the mass of an EGCG molecule, indicating that one mol-
ecule of EGCG binds to the TTR monomer under the tested
conditions.
The EGCG–TTR interaction was further characterized by ITC. The
results obtained (Q values) were analyzed so as to derive the ther-
modynamic parameters characterizing the binding event. The best
ﬁtting of the data was obtained for a model that considers one set
of binding sites. The values obtained were for the binding constant
K = 2.5  106 ± 9  105 and the enthalpy of the binding process,
DH = 30 ± 1 kJ mol1 with an occupancy of 0.145 ± 0.004 per
mole of protein. From these values we calculate a DG value of
37 kJ mol1, as well as an entropy change upon binding of
23 J K1 mol1.
3.3. Effect of EGCG on TTR tetramer stability
The effect of EGCG on TTR stability was investigated, ex vivo,
by IEF (Fig. 3A and B). Several plasma samples from heterozy-
gote carriers of TTR V30M and from control individuals were
incubated with EGCG or iododiﬂunisal (IDIF), a potent TTR stabi-
lizer, (kindly provided by Dr. Gregorio Valencia, CSIC, Barcelona,
Spain), previously tested by us and used as reference [16]. Under
the conditions used, and in the absence of stabilizers, TTR pre-
sented a characteristic band pattern, which includes the mono-
mer, an oxidized form of the monomer and several bands of
lower pI, representing different forms of tetramers. The samples
incubated with EGCG display 30% increase of the tetramer/total
protein (tetramer + monomer + oxidized monomer) ratio, in both
normal individuals and heterozygote carriers of TTR V30M
(Fig. 3C) as compared to controls, indicating that EGCG stabilizes
the TTR tetramer and it also alters TTR tetramer migration in
IEF.
3.4. Effect of EGCG on TTR aggregation in vitro
The effect of EGCG on TTR aggregation was evaluated by
ultrastructural analyses of TTR Y78F treated with two differentmbinant TTR (B). Samples were incubated with [125I] T4, with or without EGCG, and
Fig. 2. I. (A) Silver staining of proteins treated (+) or non-treated () with EGCG after SDS–PAGE. (B) Ponceau S staining of nitrocellulose membrane after electroblotting of a
gel equivalent to (A). (C) NBT/glycinate staining of the membrane of (B). II. Mass spectra of recombinant TTR WT (A) and recombinant TTR WT incubated with EGCG (B).
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ﬁbrils under physiological conditions (PBS, pH 7.4, 37 C) [16].
The results obtained are depicted in Fig. 4I, left panels: after
2 days at 37 C, the protein alone presented as a heterogeneous
preparation formed mainly by oligomers; occasionally, aggre-
gates (arrowhead) and short twisted ﬁbrils (arrow); at 4 days
incubation there was further aggregation of the protein (arrow-
heads) and formation of larger aggregates. After 6 days, the prep-
aration was largely constituted by short ﬁbrils of different
diameter (arrows) and aggregates were still present (arrow-
heads). The TTR Y78F preparations treated with EGCG were eval-
uated at the same time points: after 2 days at 37 C, small
aggregates (arrowhead, middle panel, 2 days) and oligomers
were detected in the 10 EGCG concentration but no short ﬁ-
brils were visible while incubation with EGCG 100 resulted in
round particles resembling the soluble protein after 2 days incu-
bation (Fig. 4 right panel, arrowheads). This effect was main-
tained throughout the period studied (right panels, 4 and
6 days). Similar results were achieved using EGCG 10x, at later
stages (4 and 6 days, Fig. 4 middle panels). Our results indicate
that EGCG is able to prevent TTR Y78F aggregation in vitro.3.5. Effect of EGCG on TTR aggregation in a cell culture system
The effect of EGCG on TTR aggregation was also investigated in a
rat Schwannoma cell line that secretes TTR L55P to the medium
where it forms small aggregates [16]. The aggregated protein is re-
tained in a membrane ﬁlter and is immunodetected by an anti-TTR
antibody. In the present work, we added EGCG to the cells growing
mediumandcomparedwith theeffectof iododiﬂunisal [16]. Theblot
and relative effect of EGCG on TTR aggregation are presented in
Fig. 4II. The inhibition of TTR aggregation is higher in the medium
of EGCGtreated cells than in themediumof iododiﬂunisal (reference
compound) treated cells relative to control medium, non-treated
cells. The results conﬁrm that EGCG inhibits TTR aggregation in this
cell system.
3.6. Effect of EGCG on TTR ﬁbril formation
The action of EGCGwas also tested in pre-formed aggregates pre-
pared from TTR Y78F, TTR WT and TTR V30M. These preparations
were incubated with or without EGCG (100 molar excess) for
18 days at 37 C.
Fig. 3. Analysis of plasma TTR by IEF after Coomassie Blue staining (A) and silver staining (B). Samples treated with EGCG present stronger TTR tetramer bands and less
intense reduced and oxidized monomer bands as compared to controls. These gels are representative of others run in parallel. (C) The histogram shows densitometry of IEF
gel: TTR tetramer/total TTR bands ratio for normal and V30M TTR protein, ***P 6 0.001.
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EGCG addition, the preparation was composed mainly by oligo-
mers, small aggregates and short twisted ﬁbrils (day 0). After
2 days incubation with EGCG only a small number of aggregates
and short ﬁbrils were detected, as compared to the control (data
not shown) indicating that EGCG disrupted TTR Y78F ﬁbrils. This
effect was even more evident at 4 days incubation, when the prep-
aration was mainly constituted by small spherical (off-pathway)
aggregates. Extended incubation for 18 days showed increase of
the number of small round species throughout the preparation
(data not shown).
Concerning TTR WT and V30M ﬁbrils, formed by acidiﬁcation, a
similar ﬁbril disruption effect was achieved in the presence of
EGCG for the same time points (4 and 18 days) (data not shown).
4. Discussion
In this work we investigated the effect of EGCG on TTR amyloid
ﬁbril formation. We demonstrate that EGCG binds to TTR in vitroand ex vivo it inhibits TTR amyloid ﬁbril formation in vitro and
in a cellular system.
TTR interaction with EGCG is very stable since it is resistant to
highly denaturing conditions and was detectable by MS analysis.
We concluded that one EGCG molecule binds to each TTR mono-
mer since only one extra peak corresponding to the mass of the
TTR monomer plus the mass of a molecule of EGCG was detected.
The TTR–EGCG interaction was further characterized by ITC. The
value obtained for the binding constant shows that the ligand does
bind strongly to the protein under the studied conditions even
though the occupancy obtained was very low.
Curiously, the binding of EGCG to TTR induces a signiﬁcant
alteration of TTR migration in electrophoresis. The same does not
happen with TTR ligands that bind at the T4 binding channel as
is the case of most of the TTR ﬁbril inhibitors known [23]. This re-
ﬂects the different mode of binding of EGCG as compared to other
TTR inhibitors. Indeed we were expecting that EGCG competed
with T4 for the binding to TTR because there are reports on the
competition of ﬂavonoids [13]. EGCG does not bind at the T4 bind-
Fig. 4. I. TEM analysis of TTR Y78F aggregation in the presence or absence of EGCG (10 or 100 EGCG molar excess), at different time points. II. (A) Filter assay of the
medium from cells grown in the absence (control) or in the presence of EGCG or iododiﬂunisal (IDIF). (B) Representation of the percentage of aggregation inhibition based on
quantiﬁcation of the dots obtained in A (*P 6 0.05).
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the molecule, altering its conformation and consequently its elec-
trophoretic mobility. The results obtained by IEF in partial denatur-
ing conditions suggest that, ex vivo, EGCG induces TTR stabilization
since there is a decrease in the amount of TTR monomer in the
treated samples as compared to the non-treated ones. In addition,
the amount of TTR tetramer increases and there is also an alter-
ation of the TTR tetramer migration in this electrophoresis system.
Stabilization of the TTR tetramer is one of the mechanisms by
which TTR amyloid ﬁbril formation inhibitors might act. Thus,
TTR stabilization by EGCG can explain the inhibition of TTR aggre-
gation as studied by TEM and cell culture studies. A recent report
on the effects of EGCG on a-synuclein and Ab-42 [1] suggests that
EGCG binds to unfolded proteins and redirect them to an alterna-
tive non-amyloidogenic aggregation pathway. However the possi-
bility of EGCG binding to structured proteins is not excluded, aswell as the possibility of dissociation and remodeling of pre-
formed toxic amyloid aggregates [1]. More recently, binding of
EGCG to native folded prion protein has been reported. This inter-
action promotes the formation of random coil structures and leads
to aggregation in an amorphous non-ﬁbrillar form of the protein
[24]. In either case, binding of EGCG to the unfolded or folded amy-
loidogenic protein opens new hypotheses to interfere with the
amyloid ﬁbril formation process. We further veriﬁed that EGCG
also has the capability to function as an amyloid ﬁbril disruptor
in vitro through its action over pre-formed aggregates.
Most of the previously proposed inhibitors of TTR amyloid ﬁbril
formation raise problems of toxicity and selectivity of binding to
TTR [11]. Concerning EGCG, the highest dosages tested in humans
refer to safe administration of 800 mg/day for at least 4 weeks
[25,26] however this dosage results in a peak plasma concentration
of EGCG of approximately 1 lM [26]. This value corresponds only
Fig. 5. Effect of EGCG on TTR Y78F pre-formed ﬁbrils (day 0). Aliquots of the preparation were incubated in the absence (control) or presence of EGCG (100 molar excess)
and observed 4 days after incubation by TEM.
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ent work we used an EGCG excess of 10–100 times TTR concentra-
tion. We also must consider that the interaction of EGCG with TTR
is not speciﬁc, EGCG binds to other amyloidogenic proteins and
most importantly it binds to serum albumin [27]. However we
should stress that we only tested EGCG in vitro and that the re-
peated administration of the compound in a therapeutic approach
should result in an increase of the bioavailability of the compound.
Thus, only in vivo studies using animal models for TTR amyloidosis
[28] will allow evaluation of the usefulness of this compound on
therapy for TTR amyloidoses.
It seems also relevant that EGCG crosses the blood–brain barrier
[29] and therefore it can bind TTR in the cerebrospinal ﬂuid. TTR is
a plasma protein mainly synthesized by the liver but it is also pro-
duced by the choroid plexus of the brain and is secreted to the
cerebrospinal ﬂuid where it is a major protein component [30].
In most cases of TTR amyloidosis there is no amyloid deposition
in the central nervous system but there are a few TTR variants
(about 10 variants) associated with TTR amyloid deposition in
the leptomeninges [31]. Thus, EGCG therapy might be particularly
important in those cases.
In conclusion, studies of EGCG binding to TTR should proceed in
order to characterize, at the molecular level, the interaction of TTR
with EGCG, in particular the amino acid residues involved. It would
be interesting to investigate the inﬂuence of TTR ligands, other
than T4, in particular RBP (retinol binding protein) on EGCG–TTR
interaction. Taken together the results obtained prompt us to pro-
ceed with in vivo studies, in particular with the study of the effects
of EGCG in a transgenic mice model for FAP [28].
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